幽门螺杆菌治疗指南制定与抗菌药物管理原则
本文是一篇指导幽门螺杆菌治疗指南向抗菌药物管理原则过渡的入门文章,主张放弃旧有指南原则,以绝对治愈率为核心结局指标,淘汰治愈率低于90%的方案,并强调通过疗效监测数据整合进行本地化管理。
要点
- 幽门螺杆菌治疗指南应遵循抗菌药物管理原则,优化抗生素使用并减少耐药。
- 绝对治愈率是核心结局指标,治愈率低于90%的方案应被淘汰。
- 应收集并整合疗效监测数据至本地抗菌药物管理项目以指导实践。
核心结论
- 幽门螺杆菌治疗指南需转向抗菌药物管理原则,以绝对治愈率为核心,淘汰低效方案并加强监测。
研究设计与样本
- 本文为指南制定入门指导,来自Clin Gastroenterol Hepatol,未报告具体研究设计与样本量。
主要发现
- 抗菌药物管理的目标是优化抗生素使用并减少耐药,关键结局指标为绝对治愈率。
- 比较试验应局限于能可靠产生高治愈率(如约95%)的方案,失败率高的方案应放弃。
- 常规疗效监测数据可作为药敏试验的间接替代方法,应收集并整合至本地管理项目。
关键数值与推荐
- 治愈率低于90%的治疗方案应被视为不可接受并放弃。
- 比较试验应 reliably 产生高治愈率(例如约95%)。
- 治疗推荐应与美国感染病学会关于耐药病原体抗菌药物优效性和病原体特异性临床试验的白皮书兼容。
临床怎么用
- 临床应仅使用优化后的幽门螺杆菌治疗方案,并淘汰不含贡献抗生素的方案。
- 应常规收集疗效监测数据,并与本地抗菌药物管理项目共享整合以指导处方和公共卫生决策。
局限性
- 原文未报告具体研究数据、样本量或统计值,本文为概念性指导文章。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
We provide a primer to assist in the difficult transition of Helicobacter pylori therapy guidelines to those that adhere to the principles of antimicrobial stewardship. This transition will entail abandonment of many of the principles that heretofore formed the basis of treatment guidelines and recommendations. The goals of antimicrobial stewardship include optimization of the use of antibiotics while reducing antimicrobial resistance. The critical outcome measure is absolute cure rate which largely restricts comparative trials to those which reliably produce high cure rates (eg, ∼95%). Therapies that fail to achieve at least a 90% cure rate should be abandoned as unacceptable. Because only optimized therapies should be prescribed, guidance on the principles and practices of optimization will we required. Therapies that contain antibiotics which do not contribute to outcome should be eliminated. Surveillance, one of the fundamental elements of antimicrobial stewardship, must be done to provide ongoing assurance that the recommended therapies remain effective. It is yet not widely recognized when utilizing otherwise highly successful therapies, the routine test of cure data is an indirect, surrogate method for susceptibility testing. To systematically guide therapy, test of cure data should be collected, shared and integrated into local antimicrobial stewardship programs to provide guidance regarding best practices to both prescribers and public health individuals. Treatment recommendations should be compatible with those of the American Society of Infectious Disease white paper on the conduct of superiority and organism-specific clinical trials of antibacterial agents for the treatment of infections caused by drug-resistant bacterial pathogens which include criteria for ethical active-controlled superiority studies of antibacterial agents.
引用
- Graham DY, Liou JM. Primer for Development of Guidelines for Helicobacter pylori Therapy Using Antimicrobial Stewardship. Clin Gastroenterol Hepatol. 2021. PMID: 33775895. doi:10.1016/j.cgh.2021.03.026
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。